Michael Tardugno Increases Stake in IMNN with Recent Purchase
Executive Chairman Michael Tardugno bought 42,519 shares of IMNN at $1.72 per share.
Key Points
- On June 25, 2026, Executive Chairman Michael Tardugno bought 42,519 shares of IMNN at $1.72 each.
- Shares of IMNN traded near $1.80 on Tuesday amid insider buying activity.
- Maxim Group initiated coverage on IMNN with a buy rating and a $10 price target in April 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Michael Tardugno, the Executive Chairman of IMNN, recently increased his stake in the company. On June 25, 2026, Tardugno purchased 42,519 shares at an average price of $1.72 per share, totaling $73,132.68. This move underscores his confidence in the company's prospects.
Insider Buying and Selling at Imunon, Inc.
The recent insider activity at IMNN included several key figures from the company. Alongside Michael Tardugno, who bought a total of 42,519 shares, Chief Medical Officer Douglas Vincent Faller acquired 21,896 shares at the same price of $1.72 on June 25. Stacy Lindborg, the President and CEO, purchased 67,150 shares on the same day, also at $1.72 per share. Earlier in June, Lindborg and Tardugno made additional purchases at slightly higher prices.
Other Institutional Activity in IMNN
Institutional investors have also been active in IMNN. Armistice Capital, LLC grew its holdings by 81,444 shares, ending with 348,330 shares valued at approximately $1.02 million, representing a 30.5% increase. Vanguard Capital Management LLC opened a new position with 48,056 shares worth about $141,285. Geode Capital Management, LLC increased its stake by 11,989 shares, bringing its total to 33,211 shares valued at $97,644, marking a 56.5% increase. Meanwhile, Riverview Capital Advisers, LLC maintained its position with 34,364 shares.
Analysts Set New Price Targets
Analysts have been optimistic about IMNN's potential. On April 17, 2026, Maxim Group initiated coverage on the stock with a buy rating and a price target of $10. This reflects strong expectations for the company's future performance.
About IMNN
IMNN operates in the biotechnology sector, focusing on developing innovative therapies for unmet medical needs. The company is dedicated to advancing its pipeline of products to improve patient outcomes. With headquarters in the United States, IMNN is led by a team of experienced executives committed to driving growth and scientific progress.
Bottom Line
Michael Tardugno's recent purchase of IMNN shares highlights insider confidence in the company's future. This activity, along with institutional moves and positive analyst coverage, suggests that the market is keeping a close eye on IMNN's developments. As always, it's important to remember that insider transactions can be part of a broader strategy and may not necessarily indicate the company's current financial health or future stock performance.
Get Imunon, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IMNN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.